


Purified anti-human CD135 (Flt-3/Flk-2)

Catalog # / Size: 2166510 / 100 µg
Clone: BV10A4H2
Isotype: Mouse IgG1, κ
Immunogen: BV-173 pro-B cell line
Reactivity: Human
Preparation: The antibody was purified by affinity chromatography.
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Concentration: 0.5



Human pre-B leukemia cell line REH stained with purified BV10A4H2, followed by biotinylated anti-mouse IgG and Sav-PE

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 microg per 10^6 cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application References: 1. Broudy VC, *et al.* 1999. *Blood* 94:1979. (IF, IP)
2. Yoshino N, *et al.* 2000. *Exp. Anim. (Tokyo)* 49:97. (FC)
3. Nagano M, *et al.* 2007. *Blood* 110:151. (FC) [PubMed](#)

Description: CD135 is a 130-160 kD type III tyrosine kinase receptor expressed on CD34⁺ hematopoietic stem cells, myelomonocytic progenitors, primitive B cell progenitors, and thymocytes. CD135 is also expressed on malignant hematopoietic cells including AML, ALL and CML-BC. CD135, also known as FMS-like tyrosine kinase-3, FLT3, STK-1, and Flk-2, is a growth factor receptor that binds the FLT3 ligand to promote the growth and differentiation of primitive hematopoietic cells. The intracytoplasmic domain of CD135 is modified by phosphorylation and has been shown to interact with Grb2, SOCS1, VAV1, and Shc.

Antigen References: 1. Rappold I, *et al.* 1997. *Blood* 90:111.
2. Rosnet O, *et al.* 1996. *Acta Haematol.* 95:218.
3. Rosnet O, *et al.* 1996. *Leukemia* 10:238.
4. Bertho JM, *et al.* 2000. *Scand. J.*